THE EVOLUTION OF TARGETABLE ONCOGENIC DRIVERS IN NSCLC: NOVEL TREATMENT PARADIGMS

17 OCTOBER 2017
07:00–08:00
ROOM F203+204
YOKOHAMA, JAPAN
PROGRAM
THE EVOLUTION OF TARGETABLE ONCOGENIC DRIVERS IN NSCLC: NOVEL TREATMENT PARADIGMS

OBJECTIVES

Review our current knowledge of the oncogenic drivers in NSCLC and the clinical and prognostic significance of specific molecular targets

Discuss the clinical evidence supporting ALK tyrosine kinase inhibitors (TKIs) in first- and second-line management of NSCLC

Highlight recent advances in the development of therapeutics targeting newly uncovered molecular pathways in NSCLC, with a focus on BRAF

Explore how recent treatment advances may be applied in real-world clinical practice to ensure optimal outcomes for patients

AGENDA

07:00–07:05
WELCOME AND INTRODUCTION
Solange Peters (Switzerland)

07:05–07:20
NSCLC AS A MODEL FOR PRECISION ONCOLOGY
Benjamin Solomon (Australia)

07:20–07:35
MANAGEMENT OF ALK+ NSCLC: A RAPIDLY CHANGING LANDSCAPE
Solange Peters (Switzerland)

07:35–07:50
PROGRESS IN THE TREATMENT OF BRAF-MUTATED NSCLC: WHERE ARE WE NOW?
David Planchard (France)

07:50–08:00
EXPERT PANEL Q&A (INCLUDING BRIEF SUMMARY AND CLOSE)
All

Breakfast will be available ahead of this symposium

This scientific meeting may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or material was developed for use outside of the USA, is intended for non-US HCPs, and is to be used in accordance with local laws and regulations.